Skip to main content
SpringerLink
Log in

Safety of Clopidogrel vs. Ticagrelor in Dual Antiplatelet Therapy Regimens for High-Bleeding Risk Acute Coronary Syndrome Patients: A Comprehensive Meta-analysis of Adverse Outcomes

  • Review article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

Introduction

Patients of acute coronary syndrome (ACS) at a high-bleeding risk (HBR) often require dual antiplatelet therapy (DAPT) to reduce the risk of recurrent cardiovascular events. Clopidogrel and ticagrelor are the most commonly used antiplatelet agents in DAPT regimens. However, the safety profiles of these drugs in ACS patients at HBR remain a subject of ongoing debate.

Aim

To investigate any difference between the safety of clopidogrel and ticagrelor used as a part of DAPT regimen in ACS patients at HBR.

Methods

A systematic search on PubMed, Cochrane Library, and Google Scholar was conducted to identify experimental and observational studies published up to the knowledge cutoff date in September 2023. Studies comparing the safety of clopidogrel and ticagrelor in ACS patients at HBR were included for analysis. The primary outcomes assessed were major bleeding events, stroke, and myocardial infarction (MI), while secondary outcomes included all-cause mortality, major adverse cardiac and cerebrovascular events (MACCE), and net adverse clinical and cerebral events (NACCE).

Results

We included a total of 8 observational studies in our meta-analysis. The pooled analysis revealed a statistically significant increase in the risk of MI (pooled RR = 1.43; 95% CI 1.12–1.83; P = 0.005) in the patients using clopidogrel. There were no statistically significant differences in major bleeding events (pooled RR = 0.94; 95% CI 0.82–1.09; P = 0.44), stroke (pooled RR = 1.36; 95% CI 0.86–2.14; P = 0.18), all-cause mortality (pooled RR = 1.17; 95% CI 0.97-1.41; P = 0.10), MACCE (pooled RR = 1.07; 95% CI 0.76–1.50; P = 0.69) and NACCE (pooled RR = 0.95; 95% CI 0.66–1.37; P = 0.78) between the two groups. Subgroup analyses based on region were performed.

Conclusion

Both drugs are generally safe for treating ACS patients with HBR at baseline, although a higher risk of MI was observed with the use of clopidogrel. Nevertheless, drug choice should factor in regional variations, patient-specific characteristics, cost, accessibility, and potential drug interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed 18 Aug 2023.

  2. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, Group ESD, Wijns W, Glineur D, Aboyans V, Achenbach S, Agewall S, Andreotti F, Barbato E, Baumbach A, Brophy J, Bueno H, Calvert PA, Capodanno D, Davierwala PM, Delgado V, Dudek D, Freemantle N, Funck-Brentano C, Gaemperli O, Gielen S, Gilard M, Gorenek B, Haasenritter J, Haude M, Ibanez B, Iung B, Jeppsson A, Katritsis D, Knuuti J, Kolh P, Leite-Moreira A, Lund LH, Maisano F, Mehilli J, Metzler B, Montalescot G, Pagano D, Petronio AS, Piepoli MF, Popescu BA, Sádaba R, Shlyakhto E, Silber S, Simpson IA, Sparv D, Tavilla G, Thiele H, Tousek P, Van Belle E, Vranckx P, Witkowski A, Zamorano JL, Roffi M, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J-P, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh TA, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Sousa-Uva M, Simpson IA, Zamorano JL, Pagano D, Freemantle N, Sousa-Uva M, Chettibi M, Sisakian H, Metzler B, İbrahimov F, Stelmashok VI, Postadzhiyan A, Skoric B, Eftychiou C, Kala P, Terkelsen CJ, Magdy A, Eha J, Niemelä M, Kedev S, Motreff P, Aladashvili A, Mehilli J, Kanakakis I-G, Becker D, Gudnason T, Peace A, Romeo F, Bajraktari G, Kerimkulova A, Rudzītis A, Ghazzal Z, Kibarskis A, Pereira B, Xuereb RG, Hofma SH, Steigen TK, Witkowski A, de Oliveira EI, Mot S, Duplyakov D, Zavatta M, Beleslin B, Kovar F, Bunc M, Ojeda S, Witt N, Jeger R, Addad F, Akdemir R, Parkhomenko A, Henderson R. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165. https://doi.org/10.1093/EURHEARTJ/EHY394.

    Article  PubMed  Google Scholar 

  3. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57. https://doi.org/10.1056/NEJMOA0904327/SUPPL_FILE/NEJM_WALLENTIN_1045SA1.PDF.

    Article  CAS  PubMed  Google Scholar 

  4. Turgeon RD, Koshman SL, Youngson E, Har B, Wilton SB, James MT, Graham MM. Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA Intern Med. 2020;180:420–8. https://doi.org/10.1001/JAMAINTERNMED.2019.6447.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Zamorano JL, Levine GN, Badimon L, Vranckx P, Agewall S, Andreotti F, Antman E, Barbato E, Bassand JP, Bugiardini R, Cikirikcioglu M, Cuisset T, De Bonis M, Delgado V, Fitzsimons D, Galiè N, Gilard M, Hamm CW, Ibanez B, James S, Knuuti J, Landmesser U, Leclercq C, Lettino M, Lip G, Piepoli MF, Pierard L, Schwerzmann M, Sechtem U, Simpson IA, Uva MS, Stabile E, Storey RF, Tendera M, Van De Werf F, Verheugt F, Aboyans V, Windecker S, Coca A, Coman IM, Dean V, Delgado V, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Lancellotti P, McDonagh T, Ponikowski P, DiJ R, Shlyakhto E, Roithinger FX, Aliyev F, Stelmashok V, Desmet W, Postadzhiyan A, Georghiou GP, Motovska Z, Grove EL, Marandi T, Kiviniemi T, Kedev S, Massberg S, Di A, Kiss RG, Gudmundsdottir IJ, McFadden EP, Lev E, De Luca L, Sugraliyev A, Haliti E, Mirrakhimov E, Latkovskis G, Petrauskiene B, Huijnen S, Magri CJ, Cherradi R, Ten Berg JM, Eritsland J, Budaj A, Aguiar CT, Duplyakov D, Zavatta M, Antonijevic NM, Fras Z, Montoliu AT, Varenhorst C, Di T, Addad F, Aydogdu S, Parkhomenko A, Kinnaird T. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–60. https://doi.org/10.1093/EURHEARTJ/EHX419.

    Article  PubMed  Google Scholar 

  6. Zocca P, Kok MM, van der Heijden LC, van Houwelingen KG, Hartmann M, de Man FHAF, Stoel MG, Louwerenburg JW, Knottnerus IL, Linssen GCM, Doggen CJM, von Birgelen C. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. Int J Cardiol. 2018;268:11–7. https://doi.org/10.1016/j.ijcard.2018.03.116.

    Article  PubMed  Google Scholar 

  7. Wu H, Xiang X, Li D, Shen S, Li X. Efficacy and safety of ticagrelor compared to clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis. Curr Pharm Des. 2020;26:5988–97. https://doi.org/10.2174/1381612826666200614184007.

    Article  CAS  PubMed  Google Scholar 

  8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https://doi.org/10.1136/BMJ.N71.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV, Peterson ED, Alexander KP. Baseline risk of major bleeding in non-sT-segment- elevation myocardial infarction the CRUSADE (can rapid risk stratification of unstable angina patients suppress ADverse outcomes with early implementation of the ACC/AHA guidelines) bleeding score. Circulation. 2009;119:1873–82. https://doi.org/10.1161/CIRCULATIONAHA.108.828541.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140:240–61. https://doi.org/10.1161/CIRCULATIONAHA.119.040167.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025–34. https://doi.org/10.1016/S0140-6736(17)30397-5.

    Article  PubMed  Google Scholar 

  12. D’Ascenzo F, De Filippo O, Gallone G, Mittone G, Deriu MA, Iannaccone M, Ariza-Solé A, Liebetrau C, Manzano-Fernández S, Quadri G, Kinnaird T, Campo G, Simao Henriques JP, Hughes JM, Dominguez-Rodriguez A, Aldinucci M, Morbiducci U, Patti G, Raposeiras-Roubin S, Abu-Assi E, De Ferrari GM, Piroli F, Saglietto A, Conrotto F, Omedé P, Montefusco A, Pennone M, Bruno F, Bocchino PP, Boccuzzi G, Cerrato E, Varbella F, Sperti M, Wilton SB, Velicki L, Xanthopoulou I, Cequier A, Iniguez-Romo A, Munoz Pousa I, Cespon Fernandez M, Caneiro Queija B, Cobas-Paz R, Lopez-Cuenca A, Garay A, Blanco PF, Rognoni A, Biondi Zoccai G, Biscaglia S, Nunez-Gil I, Fujii T, Durante A, Song X, Kawaji T, Alexopoulos D, Huczek Z, Gonzalez Juanatey JR, Nie SP, Kawashiri M, Colonnelli I, Cantalupo B, Esposito R, Leonardi S, Grosso Marra W, Chieffo A, Michelucci U, Piga D, Malavolta M, Gili S, Mennuni M, Montalto C, Oltrona Visconti L, Arfat Y. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. Lancet. 2021;397:199–207. https://doi.org/10.1016/S0140-6736(20)32519-8.

    Article  PubMed  Google Scholar 

  13. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, Lipiecki J, Richardt G, Iñiguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll H-P, Morice M-C. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038–47. https://doi.org/10.1056/NEJMOA1503943/SUPPL_FILE/NEJMOA1503943_DISCLOSURES.PDF.

    Article  CAS  PubMed  Google Scholar 

  14. Gragnano F, Moscarella E, Calabrò P, Cesaro A, Pafundi PC, Ielasi A, Patti G, Cavallari I, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Pelliccia F, Gaudio C, Sasso FC, Pengo V, Gresele P, Marcucci R, Fimiani F, Vitale RA, Schiavo A, Conte M, Di Maio D, Pastori D, Menichelli D, Grossi G, Di Serafino L, Taglialatela V, Galiero R, Acierno C, del Pinto M, Gugliemini G. Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. Intern Emerg Med. 2021;16:379–87. https://doi.org/10.1007/s11739-020-02404-1.

    Article  PubMed  Google Scholar 

  15. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials. Circulation. 2011;123:2736–47. https://doi.org/10.1161/CIRCULATIONAHA.110.009449.

    Article  PubMed  Google Scholar 

  16. Wang HY, Li Y, Xu XM, Li J, Han YL. Impact of baseline bleeding risk on efficacy and safety of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention. Chin Med J (Engl). 2018;131:2017–24. https://doi.org/10.4103/0366-6999.239306.

    Article  CAS  PubMed  Google Scholar 

  17. Patti G, D’Ascenzo F, De Filippo O, Bruno F, Leonardi S, Chieffo A, Iannaccone M, Liebetrau C, Manzano-Fernández S, Gallone G, Omedè P, Cerrato E, Kinnaird T, Conrotto F, Piroli F, Henriques JPS, Wan W, Elia E, Dominguez-Rodriguez A, Raposeiras-Roubin S, Abu-Assi E, De Ferrari GM. Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study. Eur Heart J Qual Care Clin Outcomes. 2022;8:881–91. https://doi.org/10.1093/ehjqcco/qcac002.

    Article  PubMed  Google Scholar 

  18. Lee WC, Fang CY, Tsai YH, Hsieh YY, Chen TY, Fang YN, Chen HC, Wu PJ, Fang HY. Comparison of clinical outcomes between ticagrelor and clopidogrel in East-Asian patients with acute coronary syndrome: large cohort study. Am J Cardiovasc Drugs. 2023;23:573–81. https://doi.org/10.1007/s40256-023-00603-7.

    Article  CAS  PubMed  Google Scholar 

  19. Lee J, Kim MJ, Kim M, Park J, Kim H, Cho S, Choi Y, Lee J, Kim JH, Cha SJ, Kim TO, Kang DY, Lee PH, Ahn JM, Park SJ, Park DW. Validation of academic research consortium for high bleeding risk definition in East-Asian patients. JACC Asia. 2023;3:390–9. https://doi.org/10.1016/j.jacasi.2022.11.012.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT, Leiboff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med. 1991;115:256–65. https://doi.org/10.7326/0003-4819-115-4-256.

    Article  CAS  PubMed  Google Scholar 

  21. Xiao P, Xie F, Lan Y. Efficacy and safety of ticagrelor versus clopidogrel with different dosages in acute coronary syndrome patients with high GRACE and CRUSADE scores. Indian Heart J. 2021;73:273–80. https://doi.org/10.1016/j.ihj.2021.02.002.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Tjerkaski J, Jernberg T, Alfredsson J, Erlinge D, James S, Lindahl B, Mohammad MA, Omerovic E, Venetsanos D, Szummer K. Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk. Eur Heart J Cardiovasc Pharmacother. 2023. https://doi.org/10.1093/ehjcvp/pvad041.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Zocca P, van der Heijden L, Kok M, Löwik M, Hartmann M, Stoel M, Louwerenburg J, de Man F, Linssen G, Knottnerus I, Doggen C, van Houwelingen K, von Birgelen C. Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. EuroIntervention. 2017;13:1168–76. https://doi.org/10.4244/EIJ-D-17-00634.

    Article  PubMed  Google Scholar 

  24. Fordyce CB, Giugliano RP, Cannon CP, Roe MT, Sharma A, Page C, White JA, Lokhnygina Y, Braunwald E, Blazing MA. Cardiovascular events and long-term risk of sudden death among stabilized patients after acute coronary syndrome: insights from IMPROVE-IT. J Am Heart Assoc. 2022. https://doi.org/10.1161/JAHA.121.022733.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Fujisaki T, Kuno T, Ando T, Briasoulis A, Takagi H, Bangalore S. Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: systematic review and meta-analysis. Am Heart J. 2021;237:34–44. https://doi.org/10.1016/j.ahj.2021.03.009.

    Article  CAS  PubMed  Google Scholar 

  26. Xie C, Lin J, Qin Q, Zhu J. Efficacy and safety of ticagrelor in east Asian patients with acute coronary syndrome: a meta-analysis of randomized controlled trials. Anatol J Cardiol. 2022;26:434–41. https://doi.org/10.5152/AnatolJCardiol.2022.1144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bergh N, Myredal A, Nivedahl P, Petzold M, Zarin S, Wartenberg C, Wallerstedt SM. Efficacy and safety of clopidogrel versus ticagrelor as part of dual antiplatelet therapy in acute coronary syndrome—a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2022;79:620–31. https://doi.org/10.1097/FJC.0000000000001233.

    Article  CAS  PubMed  Google Scholar 

  28. Bonello L, Laine M, Lemesle G, Puymirat E, Dabry T, Thuny F, Paganelli F, Aradi D, Frere C, Burtey S, Sibbing D, Mancini J. Meta-analysis of potent P2Y12-ADP receptor antagonist therapy compared to clopidogrel therapy in acute coronary syndrome patients with chronic kidney disease. Thromb Haemost. 2018;118:1839–46. https://doi.org/10.1055/s-0038-1669426.

    Article  PubMed  Google Scholar 

  29. Gao S, Xu H, Huang S, Yuan J, Yu M. Real-world use of clopidogrel and ticagrelor in patients with myocardial infarction with nonobstructive coronary arteries: patient characteristics and long-term outcomes. Front Cardiovasc Med. 2021. https://doi.org/10.3389/fcvm.2021.807494.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kwon O, Park D-W. Antithrombotic therapy after acute coronary syndromes or percutaneous coronary interventions in East Asian populations. JACC Asia. 2022;2:1–18. https://doi.org/10.1016/j.jacasi.2021.12.005.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Wu B, Lin H, Tobe RG, Zhang L, He B. Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials. J Comp Eff Res. 2018;7:281–91. https://doi.org/10.2217/cer-2017-0074.

    Article  PubMed  Google Scholar 

  32. Kheiri B, Osman M, Abdalla A, Haykal T, Barbarawi M, Zayed Y, Hicks M, Ahmed S, Bachuwa G, Hassan M, Bhatt DL. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. J Thromb Thrombolysis. 2018;46:299–303. https://doi.org/10.1007/s11239-018-1706-2.

    Article  CAS  PubMed  Google Scholar 

  33. Yang J, Zeng P, Cai W. Comparison of treatment outcomes of ticagrelor and clopidogrel among patients undergoing percutaneous coronary intervention: a meta-analysis. Curr Med Sci. 2017;37:675–80. https://doi.org/10.1007/s11596-017-1788-7.

    Article  CAS  Google Scholar 

  34. Patlolla SH, Kandlakunta H, Kuchkuntla AR, West CP, Murad MH, Wang Z, Kochar A, Rab ST, Gersh BJ, Holmes DR, Zhao DX, Vallabhajosyula S. Newer P2Y12 inhibitors vs clopidogrel in acute myocardial infarction with cardiac arrest or cardiogenic shock: a systematic review and meta-analysis. Mayo Clin Proc. 2022;97:1074–85. https://doi.org/10.1016/j.mayocp.2022.02.016.

    Article  CAS  PubMed  Google Scholar 

  35. Goto S, Huang C-H, Park S-J, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in japanese, korean and taiwanese patients with acute coronary syndrome—randomized, double-blind, phase III PHILO study. Circ J. 2015;79:2452–60. https://doi.org/10.1253/circj.CJ-15-0112.

    Article  PubMed  Google Scholar 

  36. Levine GN, Jeong Y-H, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SC. World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11:597–606. https://doi.org/10.1038/nrcardio.2014.104.

    Article  PubMed  Google Scholar 

  37. Fan Z-G, Zhang W-L, Xu B, Ji J, Tian N-L, He S-H. Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis. Drug Des Dev Ther. 2019;13:719–30. https://doi.org/10.2147/DDDT.S196535.

    Article  CAS  Google Scholar 

  38. Wang Z, Zhou D-Y, Su Y, Si L-Y, Xu Q. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis. BMC Cardiovasc Disord. 2020;20:130. https://doi.org/10.1186/s12872-020-01403-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hong J, Turgeon RD, Pearson GJ. Switching to clopidogrel in patients with acute coronary syndrome managed with percutaneous coronary intervention initially treated with prasugrel or ticagrelor: systematic review and meta-analysis. Ann Pharmacother. 2019;53:997–1004. https://doi.org/10.1177/1060028019845334.

    Article  CAS  PubMed  Google Scholar 

  40. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan G-A, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B, Halvorsen S, James S, Abdelhamid M, Aboyans V, Marsan NA, Antoniou S, Asteggiano R, Bäck M, Capodanno D, Casado-Arroyo R, Cassese S, Čelutkienė J, Cikes M, Collet J-P, Ducrocq G, Falk V, Fauchier L, Geisler T, Gorog DA, Holmvang L, Jaarsma T, Jones HW, Køber L, Koskinas KC, Kotecha D, Krychtiuk KA, Landmesser U, Lazaros G, Lewis BS, Lindahl B, Linhart A, Løchen M-L, Mamas MA, McEvoy JW, Mihaylova B, Mindham R, Mueller C, Neubeck L, Niebauer J, Nielsen JC, Niessner A, Paradies V, Pasquet AA, Petersen SE, Prescott E, Rakisheva A, Rocca B, Rosano GMC, Sade LE, Schiele F, Siller-Matula JM, Sticherling C, Storey RF, Thielmann M, Vrints C, Windecker S, Wiseth R, Witkowski A, El Amine BM, Hayrapetyan H, Metzler B, Lancellotti P, Bajrić M, Karamfiloff K, Mitsis A, Ostadal P, Sørensen R, Elwasify T, Marandi T, Ryödi E, Collet J-P, Chukhrukidze A, Mehilli J, Davlouros P, Becker D, Guðmundsdóttir IJ, Crowley J, Abramowitz Y, Indolfi C, Sakhov O, Elezi S, Beishenkulov M, Erglis A, Moussallem N, Benlamin H, Dobilienė O, Degrell P, Balbi MM, Grosu A, Lakhal Z, ten Berg J, Pejkov H, Angel K, Witkowski A, De Sousa AM, Chioncel O, Bertelli L, Stojkovic S, Studenčan M, Radšel P, Ferreiro JL, Ravn-Fischer A, Räber L, Marjeh MYB, Hassine M, Yildirir A, Parkhomenko A, Banning AP, Prescott E, James S, Arbelo E, Baigent C, Borger MA, Buccheri S, Ibanez B, Køber L, Koskinas KC, McEvoy JW, Mihaylova B, Mindham R, Neubeck L, Nielsen JC, Pasquet AA, Rakisheva A, Rocca B, Rossello X, Vaartjes I, Vrints C, Witkowski A, Zeppenfeld K. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–826. https://doi.org/10.1093/eurheartj/ehad191.

    Article  CAS  PubMed  Google Scholar 

  41. Wang Y, Yang N, Suo M, Liu X, Wang Z, Zhang X, Liu J, Zhao D, Wu X. In-hospital outcomes of Ticagrelor versus Clopidogrel in high bleeding risk patients with acute coronary syndrome: findings from the CCC-ACS project. Thromb Res. 2022;216:43–51. https://doi.org/10.1016/j.thromres.2022.04.004.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Abdur Rehman Khalid and Farooq Ahmad contributed equally to this project and are designated as co-first authors.

Authors and Affiliations

  1. Allama Iqbal Medical College, Lahore, Punjab, Pakistan

    Abdur Rehman Khalid, Farooq Ahmad, Muhammad Ahrar Bin Naeem, Smak Ahmed, Muhammad Umar, Hassan Mehmood, Muhammad Kashif & Shazib Ali

Authors
  1. Abdur Rehman Khalid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farooq Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Muhammad Ahrar Bin Naeem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Smak Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muhammad Umar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hassan Mehmood
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Muhammad Kashif
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shazib Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdur Rehman Khalid.

Ethics declarations

Compliance with ethical standards

All ethical standards devised by the PRSIMA statement 2020 were adhered to.

Funding

No funding was required for the conduction of this review.

Conflicts of interest

None declared.

Ethical approval

Systematic reviews and meta-analyses are not subject to ethical approval.

Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 82 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khalid, A.R., Ahmad, F., Naeem, M.A.B. et al. Safety of Clopidogrel vs. Ticagrelor in Dual Antiplatelet Therapy Regimens for High-Bleeding Risk Acute Coronary Syndrome Patients: A Comprehensive Meta-analysis of Adverse Outcomes. High Blood Press Cardiovasc Prev 31, 141–155 (2024). https://doi.org/10.1007/s40292-024-00635-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-024-00635-3

Keywords

Search

Navigation